153773-82-1
中文名稱
爾他培南鈉
英文名稱
1-Azabicyclo(3.2.0)hept-2-ene-2-carboxylic acid, 3-(((3S,5S)-5-(((3-ca rboxyphenyl)amino)carbonyl)-3-pyrrolidinyl)thio)-6-((1R)-1-hydroxyethy l)-4-methyl-7-oxo-, monosodium salt, (4R,5S,6S)-
CAS
153773-82-1
分子式
C22H26N3NaO7S
分子量
499.51
MOL 文件
153773-82-1.mol
更新日期
2025/01/10 09:09:19
153773-82-1 結(jié)構(gòu)式
基本信息
中文別名
爾他培南鈉厄他培南粗品
厄他培南鈉鹽
(4R,5S,6S)-3-[[(3S,5S)-5-[[(3-羧基苯基)氨基甲酰基]吡咯烷-3-基]硫-6-(1-羥基乙基)-4-甲基-7-氧代-1-氮雜雙環(huán)[3.2.0]庚-2-烯-2-甲酸鈉鹽
(4R,5R,6S)-3-[(3S,5S)-5-[(3-羧基苯基)氨基甲?；鵠吡咯烷-3-基]硫-6-(1-羥乙基)-4-甲基-7-氧代-1-氮雜雙環(huán)[3.2.0]庚-2-烯-2-甲酸鈉鹽/厄他培南鈉鹽/爾他培南鈉鹽/呃他培南鈉鹽
英文別名
Invanz3-(((3S
L 749345
EtapeneM
Etapenem sodium
ErtapeneM Crude
ErtapeneM MonosodiuM
Ertapenem Impurity 16
Ertapenem sodium, >=97%
He Seoul sodium imipenem
所屬類別
原料藥：β-內(nèi)酰胺酶抑制劑物理化學性質(zhì)
熔點>174oC (dec.)
儲存條件-70°C
溶解度可溶于DMSO（輕微）、甲醇（輕微）、水（輕微、超聲處理）
形態(tài)粉末
顏色白色至米色
水溶解性Fully miscible in water. Soluble in DMSO.
穩(wěn)定性吸濕性、溫度敏感
常見問題列表
生物活性
Ertapenem sodium (L-749345; MK-826) 屬于長效的碳青霉烯，是一種 β-內(nèi)酰胺抗生素，具有廣泛的抗菌譜。Ertapenem sodium 對革蘭氏陽性菌和革蘭氏陰性菌均有活性，包括腸桿菌科、肺炎鏈球菌和大多數(shù)種類的厭氧菌。體外研究
Ertapenem sodium inhibits
Streptococcus pneumoniae
with MIC
50
s values < 1mg/L.
Ertapenem sodium exhibits a bactericidal mode of action as shown by time-killing curves and exhibits a short postantibiotic effect (PAE) of 1.4-2.6 h against the Gram-positive strains but no PAE against Gram-negative strains.
體內(nèi)研究
Ertapenem sodium (50 mg/kg; s.c.; q6h; for 24 hours) shows substantial bactericidal activity against
S. pneumoniae
in the murine thigh infection model.
Ertapenem sodium exhibits an AUC
0-24
of 586 mg?h/L, C
max
of 140 mg/L following subcutaneous injection (mice 50 mg/kg).
| Animal Model: | Specific-pathogen-free female ICR mice (~25 g), thigh infection model |
| Dosage: | 50 mg/kg |
| Administration: | Subcutaneous injection, q6h, for 24 hours |
| Result: | Showed substantial bactericidal activities. |
| Animal Model: | Specific-pathogen-free female ICR mice (~25 g), thigh infection model |
| Dosage: | 20 mg/kg, 50 mg/kg, 100 mg/kg (Pharmacokinetic Analysis) |
| Administration: | Subcutaneous injection |
| Result: | AUC 0-24 (586 mg?h/L), C max (140 mg/L) at 50 mg/kg q6h dosing regimen. |